Pain evaluation in Radium-223 treated castration resistant prostate cancer patients with bone metastases (PARABO)
This observational prospective single arm cohort study is designed to assess pain and bone pain related quality of life of metastatic Castration Resistant Prostate Cancer (mCRPC) patients receiving Radium-223 in a real life nuclear medicine practice setting. In addition, overall survival, time to next tumor treatment (TTNT), time to first symptomatic skeletal event (SSE), course of blood counts, and safety will be assessed.
- Adult male patients diagnosed with CRPC with symptomatic bone metastases without known visceral metastases - Decision to initiate treatment with Radium-223 was made as per investigator’s routine treatment practice
- Patients participating in an investigational program with interventions outside of routine clinical practice or participating in another observational study with Xofigo
Many locations, Germany
E-mail: [email protected]
Phone: (+) 1-888-8422937
PARABO - Pain evaluation in Radium-223 (Xofigo®) treated mCRPC patients with bone metastases – a non-interventional study in nuclear medicine centers